-
1.发明申请PREPARATION OF SUBMICRON SIZED NANOPARTICLES VIA DISPERSION AND SOLVENT OR LIQUID PHASE REMOVAL 审中-公开通过分散和溶剂或液相去除来制备亚硫酸钠纳米颗粒
公开(公告)号：WO03026611A3
公开(公告)日：2003-07-03
申请号：PCT/US0230447
申请日：2002-09-25
Applicant: BAXTER INT
Inventor： BRYNJELSEN SEAN , STERNBERG SHMUEL , DUNHAM ANDREW J , DOTY MARK J , KIPP JAMES E , JAYSWAL NAILESH , NARAYANAN KRISHNASWAMY
IPC: A61K9/14 , A61K9/19 , A61K9/51 , A61K31/496 , A61K45/00 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/20 , A61K47/24 , A61K47/28 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38 , A61K47/42 , B01J13/04
CPC classification number: A61K9/14 , A61K9/145 , A61K9/5169 , A61K9/5192 , B01J13/04
Abstract: The present invention relates to a process for preparing submicron sized nanoparticles of a poorly water soluble compound by sonicating to evaporate a portion of the organic phase or by lyophilizing a dispersion or microdispersion of a multiphase system having an organic phase and an aqueous phase, the organic phase havingthe poorly water soluble organic compound therein. The method is preferably used to prepare nanoparticles of a poorly water soluble, pharmaceutically active compound suitable for in vivo delivery, particularly by parenteral routes.
Abstract translation: 本发明涉及通过超声处理以蒸发一部分有机相或通过冻干具有有机相和水相的多相体系的分散体或微分散体来制备难溶于水的化合物的亚微米尺寸的纳米颗粒的方法，所述有机相和水相的有机相 相中其水溶性差的有机化合物。 该方法优选用于制备适于体内递送的水溶性差的药学活性化合物的纳米颗粒，特别是通过肠胃外途径。
-
公开(公告)号：WO2007032993A3
公开(公告)日：2007-05-10
申请号：PCT/US2006034891
申请日：2006-09-07
Applicant: BAXTER INT , BAXTER HEALTHCARE SA , CHAUBAL MAHESH , DOTY MARK J , KONKEL JAMIE T , RABINOW BARRETT E
Inventor： CHAUBAL MAHESH , DOTY MARK J , KONKEL JAMIE T , RABINOW BARRETT E
CPC classification number: B01J13/04 , A61K9/10 , A61K9/1271 , A61K9/145 , A61K9/146 , A61K31/436
Abstract: Submicron particles of an organic compound, such as therapeutic and diagnostic agent are disclosed. The organic compound particles are associated with a least two surfactants including a block copolymer and phospholipids conjugated with a hydrophilic polymer.
Abstract translation: 公开了有机化合物的亚微米颗粒，例如治疗剂和诊断剂。 有机化合物颗粒与至少两种表面活性剂结合，包括嵌段共聚物和与亲水聚合物共轭的磷脂。
-
公开(公告)号：WO02055059A3
公开(公告)日：2002-09-06
申请号：PCT/US0149737
申请日：2001-12-20
Applicant: BAXTER INT
Inventor： KIPP JAMES E , WONG JOSEPH CHUNG TAK , DOTY MARK J , REBBECK CHRISTINE L , BRYNJELSEN SEAN , WERLING JANE , SRIRAM RAJARAM
IPC: C07D407/14 , A61K9/10 , A61K9/14 , A61K9/16 , A61K31/495 , A61K31/496 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/20 , A61K47/24 , A61K47/28 , A61K47/34 , A61K47/36 , A61K47/38 , A61K47/42 , A61P31/10 , A61K9/20 , A61K9/51
CPC classification number: A61K31/495 , A61K9/10 , A61K9/14 , A61K9/145 , A61K9/146 , A61K9/1688 , A61K31/496
Abstract: The present invention provides a method for preparing a suspension of a pharmaceutically-active compound, the solubility of which is greater in a water-miscible first organic solvent than in a second solvent which is aqueous. The process includes the steps of : (i) dissolving a first quantity of the pharmaceutically-active compound in the water-miscible first organic solvent to form a first solution ; (ii) mixing the first solution with the second solvent to precipitate the pharmaceutically-active compound ; and (iii) seeding the first solution or the second solvent or the presuspension.
Abstract translation: 本发明提供了制备药物活性化合物的悬浮液的方法，所述药物活性化合物在水混溶性第一有机溶剂中的溶解度大于含水第二溶剂中的溶解度。 该方法包括以下步骤：（i）将第一数量的药学活性化合物溶解在可与水混溶的第一有机溶剂中以形成第一溶液; （ii）将第一溶液与第二溶剂混合以沉淀药物活性化合物; 和（iii）接种第一溶液或第二溶剂或预悬浮液。
-
4.发明申请SOLID PARTICLES COMPRISING AN ANTICONVULSANT OR AN IMMUNOSUPPRESSIVE COATED WITH ONE OR MORE SURFACE MODIFIERS 审中-公开包含抗微生物剂或用一种或多种表面改性剂涂覆的免疫抑制剂的固体颗粒
公开(公告)号：WO2004103348A3
公开(公告)日：2005-01-06
申请号：PCT/US2004015621
申请日：2004-05-19
Applicant: BAXTER INT , BARRETT RABINOW E , WERLING JANE , KONKEL JAMIE TERESA , DOTY MARK J , REBBECK CHRISTINE L
Inventor： BARRETT RABINOW E , WERLING JANE , KONKEL JAMIE TERESA , DOTY MARK J , REBBECK CHRISTINE L
Abstract: This invention pertains to the formulation of small-particle suspensions of anticonvulsants, particularly carbamazepine, for pharmaceutical use. This invention also pertains to the formulation of a small-particle suspensions of immunosuppressive agents, particularly cyclosporin, for pharmaceutical use. The particles are coated with one or more surface modifiers.
Abstract translation: 本发明涉及用于药物用途的抗惊厥药，特别是卡马西平的小颗粒悬浮液的制剂。 本发明还涉及用于药物用途的免疫抑制剂，特别是环孢菌素的小颗粒悬浮液的制剂。 颗粒被一个或多个表面改性剂涂覆。
-
5.发明申请PREPARATION OF SUBMICRON SIZED PARTICLES WITH POLYMORPH CONTROL AND NEW POLYMORPH OF ITRACONAZOLE 审中-公开具有聚合物控制和新戊酰胺的新型聚合物的亚型尺寸颗粒的制备
公开(公告)号：WO2004054500A3
公开(公告)日：2004-08-26
申请号：PCT/US0324353
申请日：2003-08-04
Applicant: BAXTER INT
Inventor： WERLING JANE , KIPP JAMES E , SRIRAM RAJARAM , DOTY MARK J , REBBECK CHRISTINE L , WONG JOSEPH CHUNG TAK
IPC: A61K9/00 , A61K31/495 , A61K9/127 , A61K9/14
CPC classification number: A61K9/14 , A61K9/0019 , A61K9/10 , A61K31/495
Abstract: The present invention provides a method of preparing particles with polymorph and size control of a pharmaceutical compound, the method including the steps of: (1) providing pharmaceutical compound in a first phase; (2) seeding the compound; (3) causing a phase change in the pharmaceutical compound to a second phase of a desired polymorphic form; and (4) wherein the mean particle size of the particles is less than 7µm. The present invention further provides a polymorphic form of itraconazole.
Abstract translation: 本发明提供一种制备具有药物化合物的多晶型物和粒度控制的颗粒的方法，所述方法包括以下步骤：（1）在第一相中提供药物化合物; （2）接种化合物; （3）引起药物化合物相变为所需多晶型物的第二相; 和（4）其中颗粒的平均粒度小于7μm。 本发明还提供了伊曲康唑的多晶型物。
-
Patent Agency Ranking6.发明申请PREMIXED AMIODARONE PARENTERAL SOLUTION AND METHOD FOR MAKING THE SAME 审中-公开预先使用的AMIODARONE公司解决方案及其制备方法
公开(公告)号：WO02078605A3
公开(公告)日：2003-02-06
申请号：PCT/US0210094
申请日：2002-03-28
Applicant: BAXTER INT
Inventor： DOTY MARK J , REBBECK CHRISTINE L , KIPP JAMES E , RAGHAVAN NEERVALUR V
IPC: C07D307/80 , A61K9/00 , A61K9/08 , A61K31/343 , A61K47/02 , A61K47/10 , A61K47/18 , A61K47/26 , A61K47/34 , A61K47/36 , A61P9/06
CPC classification number: A61K9/0019 , A61K31/343 , A61K47/26
Abstract: A premix parenteral solution for intravenous administration having amiodarone, as an active ingredient, solubilized in a solution of water for injection and about 0.4 - 12 mg/ml of a non-ionic surfactant to a concentration range of from 0.2 to 6 mg/ml is disclosed. The solution optionally may include an osmotic agent. No dilution of the solution is required before administering to a patient and the sterile packaged solution has an initial pH within the range of from about 2.9 to about 3.2, preferably about 3.1. Additionally, a method for producing an amiodarone solution suitable for intravenous administration is further disclosed.
Abstract translation: 用于静脉内给药的预混合肠胃外溶液，其具有溶解于注射用水和约0.4-12mg / ml非离子表面活性剂的胺碘酮作为活性成分，浓度范围为0.2至6mg / ml， 披露。 溶液任选地可以包括渗透剂。 在给予患者之前不需要稀释溶液，无菌包装溶液的初始pH范围为约2.9至约3.2，优选约3.1。 此外，还公开了适用于静脉内给药的胺碘酮溶液的制备方法。
-
公开(公告)号：WO0174395A3
公开(公告)日：2002-02-07
申请号：PCT/US0110598
申请日：2001-03-30
Applicant: BAXTER INT
Inventor： KIPP JAMES E , DOTY MARK J , REBBECK CHRISTINE L , EILERT JAN Y
IPC: A61K9/08 , A61K9/00 , A61K31/34 , A61K31/343 , A61K47/04 , A61K47/10 , A61K47/12 , A61K47/18 , A61K47/20 , A61K47/26 , A61P9/06
CPC classification number: A61K9/0019 , A61K31/34 , A61K47/12
Abstract: The present invention provides an amiodarone parenteral solution suitable for intravenous administration without the necessity of dilution. The parenteral solution has an amiodarone concentration from 0.2 to 10 mg/ml and a buffer solution selected from the group consisting of lactate buffer, methanesulfonate buffer, or combinations thereof, the solution having a pH within the range from approximately 2.5 - 4.5.
Abstract translation: 本发明提供了一种适于静脉内给药而不需要稀释的胺碘酮肠胃外溶液。 肠胃外溶液具有0.2至10mg / ml的胺碘酮浓度和选自乳酸盐缓冲液，甲磺酸盐缓冲液或其组合的缓冲溶液，该溶液的pH值在约2.5-4.5的范围内。
-
公开(公告)号：DE112012006137T8
公开(公告)日：2015-02-19
申请号：DE112012006137
申请日：2012-03-28
Applicant: BAXTER HEALTHCARE SA , BAXTER INT
Inventor： KUU WEI-YOUH , DOTY MARK J , HURST WILLIAM S , REBBECK CHRISTINE L
IPC: F26B5/06
-
公开(公告)号：DE60234618D1
公开(公告)日：2010-01-14
申请号：DE60234618
申请日：2002-10-18
Applicant: BAXTER INT
Inventor： KIPP JAMES E , DOTY MARK J , REBBECK CHRISTINE L , BRYNJELSEN SEAN , KONKEL JAMIE TERESA
IPC: A61K9/10 , A61K8/02 , A61K8/04 , A61K8/06 , A61K8/34 , A61K8/35 , A61K8/36 , A61K8/365 , A61K8/37 , A61K8/39 , A61K8/40 , A61K8/41 , A61K8/44 , A61K8/46 , A61K8/60 , A61K8/64 , A61K8/73 , A61K8/86 , A61K8/89 , A61K8/891 , A61K9/107 , A61K9/14 , A61K31/12 , A61K31/4985 , A61K31/58 , A61K47/02 , A61K47/06 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/16 , A61K47/18 , A61K47/20 , A61K47/26 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38 , A61K47/42 , A61K47/44 , A61K47/46 , A61Q19/00
Abstract: The present invention discloses a composition of a stable suspension of a poorly water soluble pharmaceutical agent or cosmetic in the form of particles of the pharmaceutical agent or cosmetic suspended in a frozen aqueous matrix and method for its preparation. The composition is stable for a prolonged period of time, preferably six months or longer and is suitable for parenteral, oral, or non-oral routes such as pulmonary (inhalation), ophthalmic, or topical administration.
-
公开(公告)号：DE60225122T2
公开(公告)日：2009-03-05
申请号：DE60225122
申请日：2002-03-28
Applicant: BAXTER INT
Inventor： DOTY MARK J , REBBECK CHRISTINE L , KIPP JAMES E , RAGHAVAN NEERVALUR V
-
-
-
-
-
-
-
-
-
Search Results
75
records
(took 0.024 seconds)
